PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way

BACKGROUND: Various tumors are insensitive to immune checkpoint blockade (ICB) therapy. Toll-like receptors (TLRs) establish the link between innate and adaptive immunity, which can assist T-cell activation and serve as promising targets for combination to enhance ICB therapy. Here, we aimed to impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xiaolu, Long, Yiru, Chen, Binfan, Tong, Yongliang, Shan, Mengwen, Jia, Xiaomin, Hu, Chao, Liu, Meng, Zhou, Ji, Tang, Feng, Lu, Henglei, Chen, Runqiu, Xu, Pan, Huang, Wei, Ren, Jin, Wan, Yakun, Sun, Jianhua, Li, Jia, Jin, Guangyi, Gong, Likun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577932/
https://www.ncbi.nlm.nih.gov/pubmed/36253000
http://dx.doi.org/10.1136/jitc-2022-004590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577932/
https://www.ncbi.nlm.nih.gov/pubmed/36253000
http://dx.doi.org/10.1136/jitc-2022-004590

Ejemplares similares